Trial · NCT06013241
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
NCT06013241, Phase 2, Completed, Insmed Incorporated
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP). Trials, record NCT06013241. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06013241
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
- NCT number
- NCT06013241
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 288 participants, actual
- Lead sponsor
- Insmed Incorporated
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS)
- First posted
- 2023-08-28
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24 | Baseline and Week 24 | |
| Secondary | Change From Baseline in Percentage of Sinus (Maxillary and Ethmoid) Opacification as Measured by Volumetry at Week 24 | Baseline and Week 24 | The computed tomography (CT) scan performed during Screening (considered as Baseline) and at Week 24 will be used for the volumetric assessment of maxillary and ethmoid sinus opacification. |
| Secondary | Change From Baseline in Modified Lund-MacKay (LMK) Computed Tomography (CT) Score at Week 24 | Baseline and Week 24 | |
| Secondary | Proportion of Participants Requiring Rescue (Antibiotics, Systemic Corticosteroids [SCS], and/or Nasal Surgery) due to Worsening of any Chronic Rhinosinusitis (CRS) Symptoms up to Week 24 | Baseline up to Week 24 | |
| Secondary | Change From Baseline to the 28-day Average of Daily Nasal Congestion Score (NCS) at Week 24 | Baseline and Week 24 | |
| Secondary | Change From Baseline to the 28-day Average of Daily Peak Nasal Inspiratory Flow (PNIF) at Week 24 | Baseline and Week 24 | |
| Secondary | Change From Baseline in Sino-Nasal Outcome Test (SNOT-22) Total Score at Week 24 | Baseline and Week 24 | |
| Secondary | Plasma Concentration of Brensocatib | Pre-dose and at multiple timepoints post-dose up to Week 24 | |
| Secondary | Percentage of Participants who Experienced at Least One Adverse Event (AE) | Up to 28 weeks | Determination of the safety and tolerability of brensocatib compared with placebo. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06013241
GET https://conductscience.org/api/trials/v1/NCT06013241/registered